Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411524 | 1.00 | PTGDR2 (0.79) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5411534 | 1.00 | PTGDR2 (0.79) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4123558 | 0.86 | LMNA (0.59) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4190759 | 0.86 | LMNA (0.59) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4190766 | 0.86 | LMNA (0.59) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5391999 | 0.84 | PTGDR2 (0.80) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5391983 | 0.84 | PTGDR2 (0.80) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5391987 | 0.84 | PTGDR2 (0.80) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL18456873 | 0.82 | LMNA (0.56) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4115575 | 0.82 | PTGDR2 (0.68) | PTGDR2LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | PFIZER INC | 2007-08-23 | — | — | US | disclosed |
| US-7220760-B2 | Quinoline derivatives as CRTH2 antagonists | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1556356-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER LAMBERT CO (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1556356-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | WARNER-LAMBERT COMPANY LLC | 2004-07-08 | — | — | US | disclosed |
| EP-1435356-A1 | Quinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2004035543-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CRTH2 ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1413306-A1 | Tetrahydroquinoline derivatives as CRTH2 antagonists | Warner-Lambert Company LLC (US) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132772-A1 | 1-carbonyl-4-carbonylaminotetrahydroquinoline derivatives; especially treating asthma and allergic rhinitis | HRH1, HRH2, HRH4 | PTGDR2 748/4885LMNA 2805/4885SMN1; SMN2 4792/4885 |
| US-20070197587-A1 | Quinoline Derivatives as CRTH2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 120/4885LMNA 3648/4885SMN1; SMN2 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.